Selnoflast (monopotassium)

Selnoflast (RO7486967) monopotassium, formerly somalix/RG6418/IZD334 monopotassium, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast monopotassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast monopotassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2][3].

Product Specifications

CAS Number

[2260969-37-5]

Product Name Alternative

Somalix (monopotassium) ; RO-7486967 (monopotassium) ; IZD334 (monopotassium)

UNSPSC

12352005

Target

Interleukin Related; NOD-like Receptor (NLR)

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

O=C([N-]S(=O)(C1CCN(CC)CC1)=O)NC2=C(CCC3)C3=CC4=C2CCC4.[K+]

Molecular Formula

C20H28KN3O3S

Molecular Weight

429.62

References & Citations

[1]Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13 (11) :e1471. |[2]Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.|[3]Silvis MJM, et al., NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines. 2022 Nov 28;10 (12) :3056.